<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:14:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6759889" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6759889</identifier>
        <datestamp>2019-09-30</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6759889</article-id>
              <article-id pub-id-type="pmcid">PMC6759889</article-id>
              <article-id pub-id-type="pmc-uid">6759889</article-id>
              <article-id pub-id-type="pmid">31423869</article-id>
              <article-id pub-id-type="pmid">31423869</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.119.013098</article-id>
              <article-id pub-id-type="publisher-id">JAH34260</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Kidney in Cardiovascular Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of Baseline Kidney Function on the Risk of Recurrent Stroke and on Effects of Intensive Blood Pressure Control in Patients With Previous Lacunar Stroke: A Post Hoc Analysis of the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)</article-title>
                <alt-title alt-title-type="left-running-head">Agarwal et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah34260-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Agarwal</surname>
                    <given-names>Adhish</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34260-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>adhish.agarwal@hsc.utah.edu</email>
                  </address>
                </contrib>
                <contrib id="jah34260-cr-0002" contrib-type="author">
                  <name>
                    <surname>Cheung</surname>
                    <given-names>Alfred K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34260-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34260-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34260-cr-0003" contrib-type="author">
                  <name>
                    <surname>Ma</surname>
                    <given-names>Jianing</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="jah34260-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34260-cr-0004" contrib-type="author">
                  <name>
                    <surname>Cho</surname>
                    <given-names>Monique</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34260-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34260-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34260-cr-0005" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Li</surname>
                    <given-names>Man</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34260-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34260-aff-0003">
                    <sup>3</sup>
                  </xref>
                  <address>
                    <email>man.li@hsc.utah.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah34260-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Nephrology and Hypertension</named-content>
                <institution>University of Utah</institution>
                <named-content content-type="city">Salt Lake City</named-content>
                <named-content content-type="country-part">UT</named-content>
              </aff>
              <aff id="jah34260-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Renal Section</named-content>
                <institution>VA Salt Lake City Health Care System</institution>
                <named-content content-type="city">Salt Lake City</named-content>
                <named-content content-type="country-part">UT</named-content>
              </aff>
              <aff id="jah34260-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>VA Boston Healthcare System</institution>
                <institution>VA Cooperative Studies Program</institution>
                <named-content content-type="city">Boston</named-content>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Adhish Agarwal, MD, Division of Nephrology and Hypertension, University of Utah, 30 North 1900 E, 4R 312, SOM, Salt Lake City, UT 84112. E‐mail: <email>adhish.agarwal@hsc.utah.edu</email> and Man Li, PhD, Division of Nephrology and Hypertension, University of Utah, 295 Chipeta Wy, #4000, Salt Lake City, UT 84108. E‐mail: <email>man.li@hsc.utah.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>8</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>20</day>
                <month>8</month>
                <year>2019</year>
              </pub-date>
              <volume>8</volume>
              <issue>16</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.2019.8.issue-16</issue-id>
              <elocation-id>e013098</elocation-id>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>6</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-8-e013098.pdf"/>
              <abstract id="jah34260-abs-0001">
                <sec id="jah34260-sec-0001">
                  <title>Background</title>
                  <p>We conducted a post hoc analysis of the SPS3 (Secondary Prevention of Small Subcortical Strokes) Trial to examine the association of chronic kidney disease (<styled-content style="fixed-case">CKD</styled-content>) with <italic>recurrent</italic> stroke, and to assess whether baseline renal function modifies the effects of intensive systolic blood pressure control in patients with previous stroke.</p>
                </sec>
                <sec id="jah34260-sec-0002">
                  <title>Methods and Results</title>
                  <p>A total of 3020 patients with recent magnetic resonance imaging–defined symptomatic lacunar infarctions were randomized to a systolic blood pressure target of &lt;130 mm Hg versus 130 to 149 mm Hg. Predefined primary outcomes were (all‐recurrent) stroke and a composite of stroke, acute myocardial infarction, or all‐cause death; secondary outcomes were acute myocardial infarction, all‐cause death, and intracerebral hemorrhage individually. Among 3017 patients with baseline estimated glomerular filtration rate measurements, we evaluated, using Cox proportional hazards models, the association of <styled-content style="fixed-case">CKD</styled-content> with recurrent stroke and effects of the blood pressure targets on outcomes using baseline estimated glomerular filtration rate both as a categorical and linear variable. Regardless of the randomized treatment, <styled-content style="fixed-case">CKD</styled-content> at baseline was significantly associated with an increased risk of the primary cardiovascular composite outcome (hazard ratio, 1.7; 95% CI, 1.4–2.1), and all‐recurrent stroke (1.5; 1.1–2.0). However, the effects of the lower systolic blood pressure intervention on the primary outcome were not influenced by baseline <styled-content style="fixed-case">CKD</styled-content> status (<italic>P</italic> for interaction=0.62).</p>
                </sec>
                <sec id="jah34260-sec-0003">
                  <title>Conclusions</title>
                  <p><styled-content style="fixed-case">CKD</styled-content> increases the risk of recurrent stroke by 50% in patients with previous lacunar stroke. We found no definitive evidence that renal dysfunction modifies the effects of systolic blood pressure control in patients with previous stroke. Conclusive evidence for this will require adequately powered studies with moderate‐to‐advanced <styled-content style="fixed-case">CKD</styled-content>.</p>
                </sec>
                <sec id="jah34260-sec-0004">
                  <title>Clinical Trial Registration</title>
                  <p><styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00059306.</p>
                </sec>
              </abstract>
              <abstract abstract-type="short" id="jah34260-abs-0002">
                <p>See Editorial <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/JAHA.119.013637">Makin and Whiteley</ext-link>
</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah34260-kwd-0001">high blood pressure</kwd>
                <kwd id="jah34260-kwd-0002">hypertension</kwd>
                <kwd id="jah34260-kwd-0003">lacunar stroke</kwd>
                <kwd id="jah34260-kwd-0004">renal function</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>High Blood Pressure</kwd>
                <kwd>Ischemic Stroke</kwd>
                <kwd>Nephrology and Kidney</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>National Institutes of Health–National Institute of Neurological Disorders and Stroke</funding-source>
                  <award-id>U01NS038529</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="3"/>
                <page-count count="10"/>
                <word-count count="7178"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>jah34260</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>20 August 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.7 mode:remove_FC converted:20.08.2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah34260-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2019</year>;<volume>8</volume>:<elocation-id>e013098</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.119.013098</pub-id>.)<pub-id pub-id-type="pmid">31423869</pub-id></mixed-citation>
              </p>
              <fn-group id="jah34260-ntgp-0001">
                <fn id="jah34260-note-1002">
                  <p>Some of these data were presented orally at the American Society of Nephrology (ASN) Kidney Week, October 23 to 28, 2018, in San Diego, CA.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah34260-blkfxd-0001" orientation="portrait">
                <sec id="jah34260-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah34260-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah34260-list-0001">
                        <list-item>
                          <p>We know that chronic kidney disease (CKD) increases risk of stroke; however, whether CKD increases risk of <italic>recurrent</italic> stroke has been relatively unclear.</p>
                        </list-item>
                        <list-item>
                          <p>This study shows that CKD is associated with an independent 50% increase in risk for <italic>recurrent</italic> stroke in patients with previous lacunar stroke.</p>
                        </list-item>
                        <list-item>
                          <p>We found no evidence that baseline estimated glomerular filtration rate modifies the effects of blood pressure control in patients with previous stroke.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah34260-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah34260-list-0002">
                        <list-item>
                          <p>Clinicians taking care of patients with previous stroke should be aware that the presence of CKD in these patients substantially increases risk of <italic>recurrent</italic> stroke.</p>
                        </list-item>
                        <list-item>
                          <p>Providers should take measures to reduce risk and have a low threshold for suspicion for <italic>recurrent</italic> stroke in patients with previous stroke and CKD.</p>
                        </list-item>
                        <list-item>
                          <p>We found no evidence that baseline renal function should prompt clinicians to modify BP goals in patients with previous stroke.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah34260-sec-0009">
              <p>Hypertension and chronic kidney disease (CKD) are inter‐related global public health problems and both independently increase the risk of stroke.<xref rid="jah34260-bib-0001" ref-type="ref">1</xref>, <xref rid="jah34260-bib-0002" ref-type="ref">2</xref> In the United States, more than one‐third of the population has hypertension<xref rid="jah34260-bib-0003" ref-type="ref">3</xref>, <xref rid="jah34260-bib-0004" ref-type="ref">4</xref> and around 15% of the population has CKD.<xref rid="jah34260-bib-0005" ref-type="ref">5</xref> Both hypertension and CKD could cause or result from each other,<xref rid="jah34260-bib-0006" ref-type="ref">6</xref> and because of this inter‐related pathophysiology, hypertension, CKD, and a history of previous stroke often coexist in patients.<xref rid="jah34260-bib-0007" ref-type="ref">7</xref> However, optimal blood pressure (BP) targets in patients with previous stroke, especially in those with CKD, are unclear.</p>
              <p>The SPRINT (Systolic Blood Pressure Intervention) trial reported cardiovascular benefits of an intensive systolic blood pressure (SBP) target of &lt;120 mm Hg versus the standard SBP target of &lt;140 mm Hg in high‐risk nondiabetic patients.<xref rid="jah34260-bib-0008" ref-type="ref">8</xref> This landmark trial has resulted in a wider acceptance of intensive SBP targets. The 2017 American College of Cardiology/American Heart Association BP guidelines recommend a target SBP goal of &lt;130 mm Hg for most patients, including for patients with previous stroke.<xref rid="jah34260-bib-0003" ref-type="ref">3</xref>, <xref rid="jah34260-bib-0009" ref-type="ref">9</xref>
</p>
              <p>Observational data, however, suggest that CKD may attenuate the beneficial effects of intensive SBP control.<xref rid="jah34260-bib-0010" ref-type="ref">10</xref> Randomized controlled trials (RCTs) have also not confirmed a cardiovascular benefit from intensive BP control in patients with CKD.<xref rid="jah34260-bib-0011" ref-type="ref">11</xref> A post hoc analysis of SPRINT found that in the subset of participants with moderate‐to‐advanced CKD (defined as estimated glomerular filtration rate [eGFR] of &lt;45 mL/min/1.73 m<sup>2</sup>), intensive SBP control provided little<xref rid="jah34260-bib-0003" ref-type="ref">3</xref> or no cardiovascular benefit, suggesting that CKD attenuates the benefits of intensive SBP control.<xref rid="jah34260-bib-0012" ref-type="ref">12</xref> SPRINT excluded patients with a history of stroke, and it remains unknown how renal dysfunction modifies the effects of intensive SBP control in patients with previous stroke.</p>
              <p>The SPS3 (Secondary Prevention of Small Subcortical Strokes) trial<xref rid="jah34260-bib-0001" ref-type="ref">1</xref>, <xref rid="jah34260-bib-0002" ref-type="ref">2</xref> was a National Institutes of Health–sponsored RCT that examined the cardiovascular effects of a lower SBP target of &lt;130 mm Hg versus a higher target of 130 to 149 mm Hg in patients with recent magnetic resonance imaging–defined lacunar stroke. This RCT found a <italic>significant</italic> reduction in hemorrhagic stroke with the lower SBP target and a <italic>nonsignificant</italic> reduction in all (recurrent) stroke, disabling or fatal stroke, and the cardiovascular composite outcome of myocardial infarction (MI) or vascular death.<xref rid="jah34260-bib-0002" ref-type="ref">2</xref>
</p>
              <p>It is also important to note that although CKD is an established risk factor for stroke,<xref rid="jah34260-bib-0013" ref-type="ref">13</xref>, <xref rid="jah34260-bib-0014" ref-type="ref">14</xref>, <xref rid="jah34260-bib-0015" ref-type="ref">15</xref>, <xref rid="jah34260-bib-0016" ref-type="ref">16</xref> the association between CKD and risk of <italic>recurrent</italic> stroke is less clear.<xref rid="jah34260-bib-0016" ref-type="ref">16</xref> We conducted a post hoc analysis of the SPS3 trial to examine (1) the association of CKD with recurrent stroke and (2) whether baseline eGFR modifies the effects of intensive SBP control in patients with previous stroke.</p>
            </sec>
            <sec id="jah34260-sec-0010">
              <title>Methods</title>
              <p>The SPS3 Trial data reported here are available to the public and were provided to us by the National Institute of Health–National Institute of Neurological Disorders and Stroke upon request.</p>
              <sec id="jah34260-sec-0011">
                <title>Design and Participants</title>
                <p>Details of the SPS3 study design have been previously published.<xref rid="jah34260-bib-0001" ref-type="ref">1</xref>, <xref rid="jah34260-bib-0002" ref-type="ref">2</xref> Briefly, SPS3 was a randomized, multicenter clinical trial that enrolled 3020 participants from 81 centers in North America, Latin America, and Spain. Eligible patients were at least 30 years old and had a recent (at least 2 weeks, but within 180 days) symptomatic lacunar stroke confirmed by magnetic resonance imaging. Individuals were excluded if they had a cortical or large (&gt;2 cm) subcortical stroke, a disabling stroke, a hemorrhagic stroke, or if they had advanced kidney disease, defined as an eGFR &lt;40 mL/min/1.73 m<sup>2</sup> at screening. Participants were randomized to a lower SBP target of &lt;130 mm Hg or higher target of 130 to 149 mm Hg using the prospective, randomized, open, blinded end‐point design.<xref rid="jah34260-bib-0001" ref-type="ref">1</xref> All participants signed informed consent, and the appropriate institutional review board approved the trial.<xref rid="jah34260-bib-0001" ref-type="ref">1</xref>, <xref rid="jah34260-bib-0002" ref-type="ref">2</xref>
</p>
                <p>For this post hoc analysis, we obtained de‐identified data from the SPS3 trial from the National Institute of Neurological Disorders and Stroke data repository. The institutional review board at the University of Utah granted exemption from institutional review board oversight given that this was a secondary analysis of de‐identified data. We only included the SPS3 participants who had a measure of serum creatinine at study baseline. Of the 3020 participants who entered SPS3, we excluded 3 participants who had missing measures of serum creatinine at baseline, for a final sample size of 3017 individuals.</p>
              </sec>
              <sec id="jah34260-sec-0012">
                <title>BP Targets and Management</title>
                <p>As noted above, participants were randomly assigned to a higher SBP target of 130 to 149 mm Hg or a lower target of &lt;130 mm Hg. A study physician at each study site oversaw BP management. Patients were allowed to continue their antihypertensive medications. Patients were seen monthly until their BP target was achieved and then quarterly for BP measures and medication adjustment. Patients were provided the antihypertensive medications through a study formulary, which included at least 1 drug from each of the major classes. Other details have been reported previously.<xref rid="jah34260-bib-0002" ref-type="ref">2</xref>
</p>
              </sec>
              <sec id="jah34260-sec-0013">
                <title>Study Measurements</title>
                <p>BP was measured using the Colin 8800C automated device, according to a detailed protocol based on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) guidelines.<xref rid="jah34260-bib-0017" ref-type="ref">17</xref> BP was determined by the average of the 3 BP readings separated by at least 2 minutes in the seated position. The Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation was used to calculate eGFR.<xref rid="jah34260-bib-0018" ref-type="ref">18</xref> Sociodemographic and medical history data were collected at baseline. Clinical and laboratory data were obtained at baseline and every 3 months. Other details have been outlined previously.<xref rid="jah34260-bib-0002" ref-type="ref">2</xref>
</p>
              </sec>
              <sec id="jah34260-sec-0014">
                <title>Clinical Outcomes</title>
                <p>A committee blinded to treatment arm adjudicated the outcomes, which have been previously described in detail.<xref rid="jah34260-bib-0001" ref-type="ref">1</xref> The primary end point of the SPS3 trial was reduction in all stroke. For our analyses, in addition to all recurrent stroke, we defined an additional primary outcome as the composite of all recurrent stroke or acute MI or all‐cause death. The secondary outcomes for our study were acute MI, all‐cause death, and intracerebral hemorrhage.</p>
              </sec>
              <sec id="jah34260-sec-0015">
                <title>Statistical Analysis</title>
                <p>Our first objective was to assess the associations of CKD, defined as eGFR &lt;60 mL/min/1.73 m<sup>2</sup> at baseline with the primary and secondary outcomes. We used Cox proportional hazards regression models adjusted for treatment arm and then additionally adjusted for age, sex, study sites, baseline diabetes mellitus, hypertension, coronary artery disease, use of statin, use of angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker, and SBP. We tested proportional hazards assumptions using log‐log against survival plots and Schoenfeld residuals. If multiple events of the same type occurred, we calculated the time to event as the time to first event. We censored data for patients with no events at the end of study participation or death, whichever occurred first. Our second objective was to evaluate the consistency of the effects of lower BP control on the outcomes between eGFR strata. We computed hazard ratios (HRs) and 95% CIs by 2 eGFR strata (&lt;60 and ≥60 mL/min/1.73 m<sup>2</sup>) for primary and secondary outcomes. In addition, we investigated the possibility of interaction by fitting a Cox regression for the primary and secondary outcomes with main effects for the SBP intervention and each 10 mL/min/1.73 m<sup>2</sup> increase in baseline eGFR, plus the interaction term between the SBP intervention and each 10 mL/min/1.73 m<sup>2</sup> increase in baseline eGFR. The <italic>P</italic> value for the interaction term &lt;0.1 is showing potential evidence of effect modification. In sensitivity analyses, we examined the effects of lower BP control across 4 eGFR strata (&lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup>). We conducted all analyses with the intention‐to‐treat approach and with 2‐sided tests at the 5% level of significance using R software (version 3.4.3; R Foundation for Statistical Computing, Vienna, Austria).</p>
              </sec>
            </sec>
            <sec id="jah34260-sec-0016">
              <title>Results</title>
              <sec id="jah34260-sec-0017">
                <title>Baseline Characteristics</title>
                <p>Mean age for the 3017 participants was 62.8±10.8 years, 37.1% were female, 16.3% were black, 33.2% were diabetic, 75.0% were hypertensive, and the mean eGFR at baseline was 80.5±19.0 mL/min/1.73 m<sup>2</sup>. Mean baseline SBP was 143.0±18.8, and diastolic BP was 78.3±10.6 mm Hg. Mean baseline eGFRs in the &lt;60 and ≥60 mL/min/1.73 m<sup>2</sup> subgroups were 51.0±7.0 and 86.0±15.0 mL/min/1.73 m<sup>2</sup>, respectively. Even though patients with &lt;40 mL/min/1.73 m<sup>2</sup> were excluded at screening, we found that 41 participants had an eGFR of &lt;40 mL/min/1.73 m<sup>2</sup> at baseline (using the CKD‐EPI equation). Baseline characteristics for the whole cohort and by the 2 baseline eGFR subgroups are summarized in Table <xref rid="jah34260-tbl-0001" ref-type="table">1</xref> and by the 4 eGFR subgroups are summarized in Table <xref rid="jah34260-sup-0001" ref-type="supplementary-material">S1</xref>. In general, participants with lower baseline eGFR tended to be older, have a higher baseline SBP, and more likely to be hypertensive at baseline.</p>
                <table-wrap id="jah34260-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics of the Secondary Prevention of Small Subcortical Strokes Trial Participants According to Treatment Arms and 2 Baseline eGFR Subgroups (n=3017)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline eGFR Subgroups</th>
                        <th align="left" rowspan="3" valign="top" colspan="1">All</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">&lt;60 mL/min/1.73 m<sup>2</sup>
</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">≥60 mL/min/1.73 m<sup>2</sup>
</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Higher‐Target Group (n=227)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Lower‐Target Group (n=247)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Higher‐Target Group (n=1290)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Lower‐Target Group (n=1253)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td align="left" rowspan="1" colspan="1">69.4 (10.9)</td>
                        <td align="left" rowspan="1" colspan="1">69.3 (11.4)</td>
                        <td align="left" rowspan="1" colspan="1">61.7 (10.4)</td>
                        <td align="left" rowspan="1" colspan="1">61.5 (10.1)</td>
                        <td align="left" rowspan="1" colspan="1">62.8 (10.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">91 (40.1)</td>
                        <td align="left" rowspan="1" colspan="1">125 (50.6)</td>
                        <td align="left" rowspan="1" colspan="1">438 (34.0)</td>
                        <td align="left" rowspan="1" colspan="1">464 (37.0)</td>
                        <td align="left" rowspan="1" colspan="1">1118 (37.1)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">Race/ethnicity, N (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non‐Hispanic white</td>
                        <td align="left" rowspan="1" colspan="1">128 (56.4)</td>
                        <td align="left" rowspan="1" colspan="1">134 (54.3)</td>
                        <td align="left" rowspan="1" colspan="1">630 (48.8)</td>
                        <td align="left" rowspan="1" colspan="1">638 (50.9)</td>
                        <td align="left" rowspan="1" colspan="1">1530 (50.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td>
                        <td align="left" rowspan="1" colspan="1">36 (15.9)</td>
                        <td align="left" rowspan="1" colspan="1">33 (13.4)</td>
                        <td align="left" rowspan="1" colspan="1">215 (16.7)</td>
                        <td align="left" rowspan="1" colspan="1">208 (16.6)</td>
                        <td align="left" rowspan="1" colspan="1">492 (16.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">56 (24.7)</td>
                        <td align="left" rowspan="1" colspan="1">73 (29.6)</td>
                        <td align="left" rowspan="1" colspan="1">412 (30.3)</td>
                        <td align="left" rowspan="1" colspan="1">380 (30.3)</td>
                        <td align="left" rowspan="1" colspan="1">921 (30.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other/multiple</td>
                        <td align="left" rowspan="1" colspan="1">7 (3.1)</td>
                        <td align="left" rowspan="1" colspan="1">7 (2.8)</td>
                        <td align="left" rowspan="1" colspan="1">33 (2.6)</td>
                        <td align="left" rowspan="1" colspan="1">27 (2.2)</td>
                        <td align="left" rowspan="1" colspan="1">74 (2.5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">Region, N (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">North America</td>
                        <td align="left" rowspan="1" colspan="1">134 (59.0)</td>
                        <td align="left" rowspan="1" colspan="1">164 (66.4)</td>
                        <td align="left" rowspan="1" colspan="1">848 (65.7)</td>
                        <td align="left" rowspan="1" colspan="1">812 (64.8)</td>
                        <td align="left" rowspan="1" colspan="1">1958 (64.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Latin America</td>
                        <td align="left" rowspan="1" colspan="1">55 (24.2)</td>
                        <td align="left" rowspan="1" colspan="1">57 (23.1)</td>
                        <td align="left" rowspan="1" colspan="1">297 (23)</td>
                        <td align="left" rowspan="1" colspan="1">285 (22.7)</td>
                        <td align="left" rowspan="1" colspan="1">694 (23.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Spain</td>
                        <td align="left" rowspan="1" colspan="1">38 (16.7)</td>
                        <td align="left" rowspan="1" colspan="1">26 (10.5)</td>
                        <td align="left" rowspan="1" colspan="1">145 (11.2)</td>
                        <td align="left" rowspan="1" colspan="1">156 (12.5)</td>
                        <td align="left" rowspan="1" colspan="1">365 (12.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SBP, mean (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">146.8 (21.0)</td>
                        <td align="left" rowspan="1" colspan="1">147.3 (21.0)</td>
                        <td align="left" rowspan="1" colspan="1">143.0 (18.7)</td>
                        <td align="left" rowspan="1" colspan="1">141.5 (17.8)</td>
                        <td align="left" rowspan="1" colspan="1">143.0 (18.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">DBP, mean (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">77.9 (11.6)</td>
                        <td align="left" rowspan="1" colspan="1">76.9 (11.1)</td>
                        <td align="left" rowspan="1" colspan="1">79.2 (10.6)</td>
                        <td align="left" rowspan="1" colspan="1">77.8 (10.3)</td>
                        <td align="left" rowspan="1" colspan="1">78.4 (10.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">History of CAD, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (12.8)</td>
                        <td align="left" rowspan="1" colspan="1">28 (11.3)</td>
                        <td align="left" rowspan="1" colspan="1">109 (8.4)</td>
                        <td align="left" rowspan="1" colspan="1">86 (6.9)</td>
                        <td align="left" rowspan="1" colspan="1">252 (8.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">History of CHF, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">7 (2.8)</td>
                        <td align="left" rowspan="1" colspan="1">10 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">12 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">32 (1.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">74 (32.6)</td>
                        <td align="left" rowspan="1" colspan="1">93 (37.7)</td>
                        <td align="left" rowspan="1" colspan="1">425 (32.9)</td>
                        <td align="left" rowspan="1" colspan="1">409 (32.6)</td>
                        <td align="left" rowspan="1" colspan="1">1001 (33.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">196 (86.3)</td>
                        <td align="left" rowspan="1" colspan="1">218 (88.3)</td>
                        <td align="left" rowspan="1" colspan="1">939 (72.8)</td>
                        <td align="left" rowspan="1" colspan="1">909 (72.5)</td>
                        <td align="left" rowspan="1" colspan="1">2262 (75.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">eGFR, mean (SD), mL/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">50.9 (7.1)</td>
                        <td align="left" rowspan="1" colspan="1">51.1 (6.9)</td>
                        <td align="left" rowspan="1" colspan="1">85.9 (14.9)</td>
                        <td align="left" rowspan="1" colspan="1">86.0 (15.1)</td>
                        <td align="left" rowspan="1" colspan="1">80.5 (19.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total cholesterol, mean (SD), mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">174.0 (56.8)</td>
                        <td align="left" rowspan="1" colspan="1">175.1 (52.4)</td>
                        <td align="left" rowspan="1" colspan="1">177.3 (57.6)</td>
                        <td align="left" rowspan="1" colspan="1">175.7 (55.7)</td>
                        <td align="left" rowspan="1" colspan="1">176.2 (56.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">Smoking, N (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current</td>
                        <td align="left" rowspan="1" colspan="1">32 (14.1)</td>
                        <td align="left" rowspan="1" colspan="1">27 (10.9)</td>
                        <td align="left" rowspan="1" colspan="1">275 (21.3)</td>
                        <td align="left" rowspan="1" colspan="1">282 (22.5)</td>
                        <td align="left" rowspan="1" colspan="1">616 (20.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Past</td>
                        <td align="left" rowspan="1" colspan="1">100 (44.1)</td>
                        <td align="left" rowspan="1" colspan="1">113 (45.7)</td>
                        <td align="left" rowspan="1" colspan="1">498 (38.6)</td>
                        <td align="left" rowspan="1" colspan="1">495 (39.5)</td>
                        <td align="left" rowspan="1" colspan="1">1206 (40.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never</td>
                        <td align="left" rowspan="1" colspan="1">95 (41.9)</td>
                        <td align="left" rowspan="1" colspan="1">107 (43.4)</td>
                        <td align="left" rowspan="1" colspan="1">517 (40.1)</td>
                        <td align="left" rowspan="1" colspan="1">476 (38.0)</td>
                        <td align="left" rowspan="1" colspan="1">1195 (39.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Plasma glucose, mean (SD), mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">118.9 (45.1)</td>
                        <td align="left" rowspan="1" colspan="1">127.6 (60.7)</td>
                        <td align="left" rowspan="1" colspan="1">126.9 (55.8)</td>
                        <td align="left" rowspan="1" colspan="1">125.0 (54.6)</td>
                        <td align="left" rowspan="1" colspan="1">125.6 (55.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Statin use, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">152 (67.0)</td>
                        <td align="left" rowspan="1" colspan="1">175 (70.9)</td>
                        <td align="left" rowspan="1" colspan="1">890 (69.0)</td>
                        <td align="left" rowspan="1" colspan="1">862 (68.8)</td>
                        <td align="left" rowspan="1" colspan="1">2079 (68.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Aspirin use, N (%)</td>
                        <td align="left" rowspan="1" colspan="1">130 (57.3)</td>
                        <td align="left" rowspan="1" colspan="1">129 (52.2)</td>
                        <td align="left" rowspan="1" colspan="1">731 (56.7)</td>
                        <td align="left" rowspan="1" colspan="1">707 (56.4)</td>
                        <td align="left" rowspan="1" colspan="1">1697 (56.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI, mean (SD), kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">28.8 (5.9)</td>
                        <td align="left" rowspan="1" colspan="1">28.3 (5.5)</td>
                        <td align="left" rowspan="1" colspan="1">29.3 (7.7)</td>
                        <td align="left" rowspan="1" colspan="1">29.1 (6.2)</td>
                        <td align="left" rowspan="1" colspan="1">29.1 (6.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">No. of antihypertensive drugs, mean (SD)</td>
                        <td align="left" rowspan="1" colspan="1">1.9 (1.2)</td>
                        <td align="left" rowspan="1" colspan="1">2.0 (1.2)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.5 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (1.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah34260-note-0003">
                      <p>Values for categorical variables are presented as number (percentage); values for continuous variables, as mean (SD). BMI indicates body mass index; CAD, coronary artery disease; CHF, congestive heart failure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah34260-sec-0018">
                <title>Achieved BPs</title>
                <p>Mean achieved SBPs at 1 year in the lower and higher SBP arms were 126.9 and 137.9 mm Hg, respectively, and for the &lt;60 and ≥60 mL/min/1.73 m<sup>2</sup> eGFR subgroups were 135.0 and 132.0 mm Hg, respectively. Boxplots displaying the medians and 25th and 75th percentiles of the achieved SBP and diastolic BP at 1‐year follow‐up by 2 baseline eGFR subgroups for participants in the lower and higher SBP target groups are presented in Figure <xref rid="jah34260-fig-0001" ref-type="fig">1</xref> and by 4 baseline eGFR subgroups are presented in Figure <xref rid="jah34260-sup-0001" ref-type="supplementary-material">S1</xref>. The achieved SBP was significantly higher among participants in the eGFR &lt;60 mL/min/1.73 m<sup>2</sup> compared with eGFR ≥60 mL/min/1.73 m<sup>2</sup> within both the lower‐target group (130.0±17.1 versus 126.3±13.2 mm Hg; <italic>P</italic>=0.003) and higher‐target group (140.5±14.8 versus 137.4±14.4 mm Hg; <italic>P</italic>=0.01).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah34260-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Achieved blood pressures by randomized <styled-content style="fixed-case">SBP</styled-content> intervention and 2 baseline <styled-content style="fixed-case">eGFR</styled-content> subgroups. Boxplots display the median, 25th, and 75th percentiles of the patients’ follow‐up values at 1 year for systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>;<bold> A</bold>) and diastolic blood pressure (<styled-content style="fixed-case">DBP</styled-content>;<bold> B</bold>) by randomized <styled-content style="fixed-case">SBP</styled-content> intervention and two baseline <styled-content style="fixed-case">eGFR</styled-content> groups. One hundred twenty‐three of 3017 subjects (4.1%; 68 in the higher‐target group and 55 in the lower‐target group) had missing blood pressure measurements at 1 year and were not included. eGFR indicates estimated glomerular filtration rate.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-8-e013098-g001"/>
                </fig>
              </sec>
              <sec id="jah34260-sec-0019">
                <title>Clinical Outcomes</title>
                <sec id="jah34260-sec-0020">
                  <title>Association of baseline CKD with outcomes</title>
                  <p>During the median follow‐up period of 3.7 years, there were total 474 primary outcome events (the composite of all recurrent stroke or acute MI or all‐cause death). In the subgroup <italic>with</italic> CKD (baseline eGFR of &lt;60 mL/min/1.73 m<sup>2</sup>) at baseline (N=474), 113 (23.8%) primary outcome events occurred, of which 58 (12.2%), 11 (2.3%), and 44 (9.3%) were recurrent stroke, acute MI, and all‐cause death, respectively. In the subgroup <italic>without</italic> CKD (eGFR ≥60 mL/min/1.73 m<sup>2</sup>) at baseline (N=2543), 361 (14.2%) primary outcome events occurred, of which 213 (8.4%), 52 (2%), and 96 (3.8%) were recurrent stroke, acute MI, and all‐cause death, respectively. CKD at baseline was associated with a significant 40% increase in risk for the composite outcome (HR, 1.4; 95% CI, 1.1–1.7) and with a significant 50% increase in risk for all recurrent stroke (HR, 1.5; 95% CI, 1.1–2.0; Table <xref rid="jah34260-tbl-0002" ref-type="table">2</xref>). Nevertheless, differences in risk for secondary outcomes of acute MI, all‐cause death, and intracerebral hemorrhage were not significant between subgroups with and without baseline CKD. Figure <xref rid="jah34260-fig-0002" ref-type="fig">2</xref> shows the cumulative incidence of the primary composite outcome and all recurrent stroke in patients with versus without CKD at baseline, respectively.</p>
                  <table-wrap id="jah34260-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 2</label>
                    <caption>
                      <p>Association Between Baseline CKD (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>) and Risk of Primary and Secondary Outcomes (Regardless of the SBP Intervention)</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="3" valign="top" colspan="1">Outcome</th>
                          <th align="left" colspan="8" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline eGFR Subgroups</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">&lt;60 mL/min/1.73 m<sup>2</sup> (n=474)</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">≥60 mL/min/1.73 m<sup>2</sup> (n=2543)</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Unadjusted</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Adjusted<xref ref-type="fn" rid="jah34260-note-0005">a</xref>
</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">Events N (%)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Incidence (95% CI) Per 100 PY</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Events N (%)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Incidence (95% CI) Per 100 PY</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">aHR (95% CI)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Stroke, MI, or death</td>
                          <td align="left" rowspan="1" colspan="1">113 (23.8)</td>
                          <td align="left" rowspan="1" colspan="1">6.6 (5.5, 8.0)</td>
                          <td align="left" rowspan="1" colspan="1">361 (14.2)</td>
                          <td align="left" rowspan="1" colspan="1">3.9 (3.5, 4.4)</td>
                          <td align="left" rowspan="1" colspan="1">1.7 (1.4, 2.1)</td>
                          <td align="left" rowspan="1" colspan="1">1.4E‐6</td>
                          <td align="left" rowspan="1" colspan="1">1.4 (1.1, 1.7)</td>
                          <td align="left" rowspan="1" colspan="1">4.4E‐3</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Stroke</td>
                          <td align="left" rowspan="1" colspan="1">58 (12.2)</td>
                          <td align="left" rowspan="1" colspan="1">3.4 (2.6, 4.4)</td>
                          <td align="left" rowspan="1" colspan="1">213 (8.4)</td>
                          <td align="left" rowspan="1" colspan="1">2.3 (2.0, 2.7)</td>
                          <td align="left" rowspan="1" colspan="1">1.5 (1.1, 2.0)</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                          <td align="left" rowspan="1" colspan="1">1.5 (1.1, 2.0)</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Acute MI</td>
                          <td align="left" rowspan="1" colspan="1">11 (2.3)</td>
                          <td align="left" rowspan="1" colspan="1">0.6 (0.4, 1.2)</td>
                          <td align="left" rowspan="1" colspan="1">52 (2.0)</td>
                          <td align="left" rowspan="1" colspan="1">0.6 (0.4, 0.7)</td>
                          <td align="left" rowspan="1" colspan="1">1.1 (0.6, 2.2)</td>
                          <td align="left" rowspan="1" colspan="1">0.70</td>
                          <td align="left" rowspan="1" colspan="1">1.0 (0.5, 1.9)</td>
                          <td align="left" rowspan="1" colspan="1">0.92</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">All‐cause death</td>
                          <td align="left" rowspan="1" colspan="1">44 (9.3)</td>
                          <td align="left" rowspan="1" colspan="1">2.6 (1.9, 3.5)</td>
                          <td align="left" rowspan="1" colspan="1">96 (3.8)</td>
                          <td align="left" rowspan="1" colspan="1">1.0 (0.9, 1.3)</td>
                          <td align="left" rowspan="1" colspan="1">2.5 (1.7, 3.5)</td>
                          <td align="left" rowspan="1" colspan="1">8.3E‐7</td>
                          <td align="left" rowspan="1" colspan="1">1.4 (0.9, 2.0)</td>
                          <td align="left" rowspan="1" colspan="1">0.10</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">IC hemorrhage</td>
                          <td align="left" rowspan="1" colspan="1">7 (1.5)</td>
                          <td align="left" rowspan="1" colspan="1">0.4 (0.2, 0.9)</td>
                          <td align="left" rowspan="1" colspan="1">15 (0.6)</td>
                          <td align="left" rowspan="1" colspan="1">0.2 (0.1, 0.3)</td>
                          <td align="left" rowspan="1" colspan="1">2.5 (1.0, 6.2)</td>
                          <td align="left" rowspan="1" colspan="1">0.04</td>
                          <td align="left" rowspan="1" colspan="1">1.8 (0.7, 4.8)</td>
                          <td align="left" rowspan="1" colspan="1">0.22</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah34260-note-0004">
                        <p>aHR indicates adjusted hazard ratio; CKD, chronic kidney disease; HR, hazard ratio; IC hemorrhage, intracerebral hemorrhage; MI, myocardial infarction; PY, person‐years.</p>
                      </fn>
                      <fn id="jah34260-note-0005">
                        <label>a</label>
                        <p>Adjusted for age, sex, treatment assignment, study sites, and baseline diabetes mellitus, hypertension, statin use, angiotensin‐converting enzyme inhibitor or angiotensin‐receptor blocker use, systolic blood pressure, and history of coronary artery disease.</p>
                      </fn>
                    </table-wrap-foot>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                    </permissions>
                  </table-wrap>
                  <fig fig-type="Figure" xml:lang="en" id="jah34260-fig-0002" orientation="portrait" position="float">
                    <label>Figure 2</label>
                    <caption>
                      <p>Cumulative incidence of the composite outcome and all recurrent stroke for those with and without <styled-content style="fixed-case">CKD</styled-content>. <bold>A</bold>, Composite outcome. <bold>B</bold>, All recurrent stroke. CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate HR, hazard ratio. </p>
                    </caption>
                    <graphic id="nlm-graphic-3" xlink:href="JAH3-8-e013098-g002"/>
                  </fig>
                </sec>
                <sec id="jah34260-sec-0021">
                  <title>Modification of effects of the SBP intervention on the outcomes by baseline eGFR</title>
                  <p>When stratified by 2 baseline eGFR strata, &lt;60 and ≥60 mL/min/1.73 m<sup>2</sup> (CKD and non‐CKD), the HR for the primary composite outcome was 0.98 (95% CI, 0.67–1.41) within the CKD group and 0.86 (95% CI, 0.70–1.06) within the non‐CKD group (<italic>P</italic> interaction=0.57; Figure <xref rid="jah34260-fig-0003" ref-type="fig">3</xref>). Furthermore, there was no evidence of an interaction between SBP intervention and baseline CKD for any of the outcomes, including the primary composite outcome, all recurrent stroke, all‐cause death, acute MI, or intracerebral hemorrhage events (Figure <xref rid="jah34260-fig-0003" ref-type="fig">3</xref>).</p>
                  <fig fig-type="Figure" xml:lang="en" id="jah34260-fig-0003" orientation="portrait" position="float">
                    <label>Figure 3</label>
                    <caption>
                      <p>Forest plots with hazard ratios for the effect of <styled-content style="fixed-case">SBP</styled-content> intervention on the events of primary and secondary outcomes by 2 baseline <styled-content style="fixed-case">eGFR</styled-content> subgroups. *The interaction test for each outcome compared <styled-content style="fixed-case">HR</styled-content>s below and above <styled-content style="fixed-case">eGFR</styled-content> value of 60 mL/min/1.73 m<sup>2</sup>. Composite <styled-content style="fixed-case">CV</styled-content> indicates composite cardiovascular outcome; <styled-content style="fixed-case">HR</styled-content>, hazard ratio; <styled-content style="fixed-case">IC</styled-content> hemorrhage, intracerebral hemorrhage; <styled-content style="fixed-case">MI</styled-content>, myocardial infarction; SBP, systolic blood pressure.</p>
                    </caption>
                    <graphic id="nlm-graphic-5" xlink:href="JAH3-8-e013098-g003"/>
                  </fig>
                  <p>We further examined the consistency of the SBP intervention effect on the primary and secondary outcomes across 4 strata of baseline eGFR (&lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90‐mL/min/1.73 m<sup>2</sup>). The beneficial effect of lower‐target SBP intervention on all‐cause death was attenuated with increase of eGFR (<italic>P</italic> interaction=0.04), whereas eGFR did not modify the effect on the primary composite outcome (<italic>P</italic> interaction=0.66), all recurrent stroke (<italic>P</italic> interaction=0.22), acute MI (<italic>P</italic> interaction=0.47), or intracerebral hemorrhage (<italic>P</italic> interaction=0.33; Figure <xref rid="jah34260-sup-0001" ref-type="supplementary-material">S2</xref>).</p>
                  <p>After adjustment for the linear form of baseline eGFR (each 10 mL/min/1.73 m<sup>2</sup> increase), intensive SBP control remained beneficial for the primary and secondary outcomes when compared with standard SBP control, with no significant modification by baseline eGFR on this effect (Table <xref rid="jah34260-tbl-0003" ref-type="table">3</xref>). The HR of intracerebral hemorrhage remained significantly reduced (HR, 0.37; 95% CI, 0.14–0.93; <italic>P</italic>=0.04) with adjustment for baseline eGFR. There was no evidence of interaction between SBP intervention and linear form of baseline eGFR for the primary composite outcome (<italic>P</italic> interaction=0.62), all recurrent stroke (<italic>P</italic> interaction=0.78), acute MI (<italic>P</italic> interaction=0.42), all‐cause death (<italic>P</italic> interaction=0.16), or intracerebral hemorrhage (<italic>P</italic> interaction=0.30; Table <xref rid="jah34260-tbl-0003" ref-type="table">3</xref>).</p>
                  <table-wrap id="jah34260-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 3</label>
                    <caption>
                      <p>Effects of the SBP Intervention, Baseline eGFR, and the Linear Interaction Between the SBP Intervention and Baseline eGFR for the Primary and Secondary Outcomes</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="3" valign="top" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Model 1<xref ref-type="fn" rid="jah34260-note-0007">a</xref>
</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Model 2<xref ref-type="fn" rid="jah34260-note-0008">b</xref>
</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Lower‐Target vs Higher‐Target</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Change in Each 10 mL/min/1.73 m<sup>2</sup> Increase in Baseline eGFR</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Interaction Term (Change in Lower‐Target vs Higher‐Target HR for Each 10 mL/min/1.73 m<sup>2</sup> Increase in Baseline eGFR</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Values</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Values</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">HR (95% CI)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Values</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Stroke, MI, or death</td>
                          <td align="left" rowspan="1" colspan="1">0.89 (0.75, 1.07)</td>
                          <td align="left" rowspan="1" colspan="1">0.22</td>
                          <td align="left" rowspan="1" colspan="1">0.89 (0.85, 0.93)</td>
                          <td align="left" rowspan="1" colspan="1">7.7E‐7</td>
                          <td align="left" rowspan="1" colspan="1">1.02 (0.93, 1.13)</td>
                          <td align="left" rowspan="1" colspan="1">0.62</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Stroke</td>
                          <td align="left" rowspan="1" colspan="1">0.83 (0.66, 1.06)</td>
                          <td align="left" rowspan="1" colspan="1">0.14</td>
                          <td align="left" rowspan="1" colspan="1">0.95 (0.89, 1.01)</td>
                          <td align="left" rowspan="1" colspan="1">0.12</td>
                          <td align="left" rowspan="1" colspan="1">1.02 (0.90, 1.16)</td>
                          <td align="left" rowspan="1" colspan="1">0.78</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Acute MI</td>
                          <td align="left" rowspan="1" colspan="1">0.95 (0.58, 1.56)</td>
                          <td align="left" rowspan="1" colspan="1">0.84</td>
                          <td align="left" rowspan="1" colspan="1">0.92 (0.81, 1.05)</td>
                          <td align="left" rowspan="1" colspan="1">0.22</td>
                          <td align="left" rowspan="1" colspan="1">0.90 (0.69, 1.17)</td>
                          <td align="left" rowspan="1" colspan="1">0.42</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Death (all‐cause)</td>
                          <td align="left" rowspan="1" colspan="1">0.98 (0.71, 1.37)</td>
                          <td align="left" rowspan="1" colspan="1">0.93</td>
                          <td align="left" rowspan="1" colspan="1">0.76 (0.69, 0.83)</td>
                          <td align="left" rowspan="1" colspan="1">1.7E‐9</td>
                          <td align="left" rowspan="1" colspan="1">1.14 (0.95, 1.36)</td>
                          <td align="left" rowspan="1" colspan="1">0.16</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Intracerebral hemorrhage</td>
                          <td align="left" rowspan="1" colspan="1">0.37 (0.14, 0.93)</td>
                          <td align="left" rowspan="1" colspan="1">0.04</td>
                          <td align="left" rowspan="1" colspan="1">0.76 (0.61, 0.96)</td>
                          <td align="left" rowspan="1" colspan="1">0.02</td>
                          <td align="left" rowspan="1" colspan="1">0.76 (0.45, 1.29)</td>
                          <td align="left" rowspan="1" colspan="1">0.30</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah34260-note-0017">
                        <p>eGFR indicates estimated glomerular filtration rate; HR, hazard ratio; MI, myocardial infarction; SBP, systolic blood pressure.</p>
                      </fn>
                      <fn id="jah34260-note-0007">
                        <label>a</label>
                        <p>The second to fifth columns under model 1 display the results of Cox regression analyses relating the primary and secondary outcomes to the randomized SBP intervention (HRs in the second column) and to the level of baseline eGFR at each increase of 10 mL/min/1.73 m<sup>2</sup> (HRs in the fourth column).</p>
                      </fn>
                      <fn id="jah34260-note-0008">
                        <label>b</label>
                        <p>The sixth and seventh columns display the proportional change in the HR comparing the intensive and standard SBP interventions for each 10 mL/min/1.73 m<sup>2</sup> increase in baseline eGFR under model 2, which includes main effects for the randomized SBP intervention and linear form of baseline eGFR, plus linear interactions between the randomized SBP intervention and baseline eGFR. The linear interactions were evaluated by likelihood ratio tests.</p>
                      </fn>
                    </table-wrap-foot>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                    </permissions>
                  </table-wrap>
                </sec>
              </sec>
            </sec>
            <sec id="jah34260-sec-0022">
              <title>Discussion</title>
              <p>We found that in patients with well‐defined previous lacunar stroke, baseline eGFR of &lt;60 mL/min (versus ≥60 mL/min) was significantly associated with an increased risk of all recurrent stroke and the composite outcome of stroke, acute MI or all‐cause death. Risk of recurrent stroke increased by 50% (and by 40% for the composite outcome) in patients with baseline CKD (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>) versus those without CKD even after adjusting* (*Adjusted for age, gender, treatment assignment, study sites and baseline diabetes mellitus, hypertension, statin use, ACE inhibitor or ARB use, systolic blood pressure, and history of coronary artery disease.) for other baseline variables. However, we found no evidence that baseline eGFR significantly modifies the effects of lower SBP target (&lt;130 mm Hg) on either recurrent stroke or the composite outcome, or on any of the secondary outcomes of acute MI, all‐cause death, or intracerebral hemorrhage.</p>
              <p>This post hoc analysis of SPS3 is the first to report a clear association between CKD and <italic>recurrent</italic> stroke in patients with confirmed and well‐defined previous lacunar stroke. Several previous studies show that renal dysfunction increases risk of cardiovascular events, and incident stroke,<xref rid="jah34260-bib-0019" ref-type="ref">19</xref>, <xref rid="jah34260-bib-0020" ref-type="ref">20</xref>, <xref rid="jah34260-bib-0021" ref-type="ref">21</xref> but do not show clear associations of renal dysfunction with recurrent stroke. This may be because there are few RCTs that have enrolled patients with a well‐characterized history of previous stroke. The SPS3 trial, however, included patients with well‐characterized magnetic resonance imaging–defined lacunar infarctions that occurred within 6 months before entry to the trial and thus presented an opportunity for accurately defining the association of CKD with recurrent stroke. In the previous RCTs that enrolled patients with previous stroke (PROGRESS [Perindopril pROtection aGainst REcurrent Stroke Study]<xref rid="jah34260-bib-0022" ref-type="ref">22</xref> and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]<xref rid="jah34260-bib-0023" ref-type="ref">23</xref> trials), previous stroke was not as well defined as in the SPS3 trial; nevertheless, post hoc analyses of these trials<xref rid="jah34260-bib-0024" ref-type="ref">24</xref>, <xref rid="jah34260-bib-0025" ref-type="ref">25</xref> did report increased risk of recurrent stroke with baseline CKD. Our study clarifies and defines the independent association of CKD with a 50% increase in risk of recurrent stroke in patients with a history of well‐defined previous lacunar stroke. A widely cited meta‐analysis by Lee et al published in 2010 found that an eGFR of &lt;60 mL/min/1.73 m<sup>2</sup> is associated with a 43% higher risk of primary incident stroke.<xref rid="jah34260-bib-0016" ref-type="ref">16</xref> Our results show a similar increase in risk of <italic>recurrent</italic> stroke in patients with an eGFR of &lt;60 mL/min/1.73 m<sup>2</sup>.</p>
              <p>This study is also the first to report whether baseline kidney function modifies the effects of BP control in patients with previous stroke. Although greater absolute risks magnify treatment benefits, previous data suggest that CKD attenuates the benefits of intensive BP control.<xref rid="jah34260-bib-0010" ref-type="ref">10</xref>, <xref rid="jah34260-bib-0012" ref-type="ref">12</xref> However, no such data existed for patients with previous stroke. A cohort study of US veterans with prevalent CKD (eGFR of &lt;60 mL/min/1.73 m²) suggested increased mortality when treated to an SBP of &lt;120 mm Hg versus 120 to 139 mm Hg.<xref rid="jah34260-bib-0026" ref-type="ref">26</xref> A secondary analysis of 2 community‐based, longitudinal studies (ARIC<xref rid="jah34260-bib-0027" ref-type="ref">27</xref> [Atherosclerosis Risk in Communities Study] and Cardiovascular Health Study<xref rid="jah34260-bib-0028" ref-type="ref">28</xref>) including data from 20 358 individuals showed an increased risk of stroke with an SBP of &lt;120 mm Hg in patients with CKD (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>), but not in those without CKD.<xref rid="jah34260-bib-0029" ref-type="ref">29</xref>
</p>
              <p>The SPRINT trial did show cardiovascular benefits of intensive SBP control (&lt;120 versus &lt;140 mm Hg), but was not designed to assess whether CKD modified the effects of SBP control. Post‐hoc analyses of SPRINT report conflicting results. Benefits of intensive SBP control were observed to persist in patients with CKD when baseline eGFR was used as a dichotomous variable (&lt;60 versus ≥60 mL/min/1.73 m<sup>2</sup>).<xref rid="jah34260-bib-0008" ref-type="ref">8</xref>, <xref rid="jah34260-bib-0030" ref-type="ref">30</xref> However, another post hoc analysis of SPRINT suggested that in the subset of participants with moderate‐to‐advanced CKD (defined as eGFR of &lt;45 mL/min/1.73 m<sup>2</sup>), intensive SBP control provided little or no cardiovascular benefit.<xref rid="jah34260-bib-0012" ref-type="ref">12</xref> Given that SPRINT excluded patients with a history of stroke, these analyses could not examine how renal dysfunction may modify the effects of intensive SBP control in patients with previous stroke. Another large BP target trial, the Action to Control Cardiovascular Risk in Type 2 Diabetes (ACCORD) trial, looked at the effects of similar SBP targets (&lt;120 versus &lt;140 mm Hg); however, it had a relatively small proportion (9%) of participants with baseline CKD and a poorly defined cohort of participants with previous stroke.<xref rid="jah34260-bib-0031" ref-type="ref">31</xref> In contrast, all participants of SPS3 had previous stroke, and almost 16% had baseline CKD; thus, a post hoc analysis of SPS3 data presented an opportunity for assessing how renal dysfunction may modify the effects of intensive SBP control in patients with previous stroke.</p>
              <p>It is also important to point out that elucidation of optimal BP targets in patients with previous stroke and CKD is important. Hypertension is the most prevalent risk factor for cardiovascular disease and stroke.<xref rid="jah34260-bib-0032" ref-type="ref">32</xref> BP is an important determinant of cardiovascular disease,<xref rid="jah34260-bib-0033" ref-type="ref">33</xref> and lowering of BP prevents initial<xref rid="jah34260-bib-0033" ref-type="ref">33</xref>, <xref rid="jah34260-bib-0034" ref-type="ref">34</xref> and recurrent<xref rid="jah34260-bib-0022" ref-type="ref">22</xref>, <xref rid="jah34260-bib-0035" ref-type="ref">35</xref>, <xref rid="jah34260-bib-0036" ref-type="ref">36</xref> stroke. Lacunar or small subcortical strokes account for around 25% of all ischemic strokes and may have a stronger association with hypertension than other types of strokes.<xref rid="jah34260-bib-0037" ref-type="ref">37</xref>
</p>
              <p>As noted above, we did not find any evidence that baseline CKD or eGFR modified the effects of lower (&lt;130 mm Hg) versus higher (130–149 mm Hg) SBP targets in patients with previous lacunar stroke. This may be either because eGFR does not modify the effects of SBP control in patients with previous stroke or because our study lacked power to detect small effects. The number of participants with low eGFR was relatively low (474 with &lt;60 versus 2543 with ≥60 mL/min/1.73 m²), and that was the main limitation of our study. Given that it is possible that attenuation of the benefits of SBP control is observed only with moderate‐to‐advanced CKD,<xref rid="jah34260-bib-0012" ref-type="ref">12</xref> we also assessed the effects of SBP intervention across 4 baseline eGFR strata (&lt;45, 45 to &lt;60, 60 to &lt;90, and ≥90 mL/min/1.73 m<sup>2</sup>). This helped to assess possible effects of more‐advanced CKD, but reduced the number of participants in each eGFR strata, further limiting the statistical power. Using these 4 categorical strata, we found a borderline significant interaction with all‐cause death, but not with any other outcome. This could be because of the small sample size for the eGFR &lt;45 mL/min/1.73 m<sup>2</sup> category; categorizing continuous variables like eGFR may impair the statistical power to detect meaningful differences.</p>
              <p>In addition to having relatively few participants with CKD, especially moderate‐to‐advanced CKD, our study had some other limitations. The SPS3 trial evaluated recurrent stroke only in patients with previous lacunar stroke; thus, the results may not be generalizable to other types of stroke. In addition, the SPS3 trial had lower than anticipated event rates. The post hoc nature of our analyses could only detect association, not causality. On the other hand, our study had certain strengths. Magnetic resonance imaging confirmation and characterization of previous lacunar stroke ensured homogeneity of the study population, unlike any previous study. The SPS3 was a well‐designed and well‐conducted trial, and we studied effects of contemporaneously relevant SBP targets of &lt;130 mm Hg (the target SBP recommended by the 2017 American College of Cardiology/American Heart Association guidelines for patients with previous stroke) versus a higher target of 130 to 149 mm Hg.</p>
              <p>In conclusion, we found an independent 50% increase in risk for <italic>recurrent</italic> stroke in patients with CKD (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>). Clinicians treating patients with previous stroke should be aware of this increased risk with CKD, take measures to reduce the risk of recurrent stroke, and have a low threshold for clinical suspicion for recurrent stroke in patients with CKD. It remains possible that renal dysfunction modifies the effects of BP control in patients with previous stroke, but we found no definitive evidence of that. We need large‐scale BP target trials for those with moderate‐to‐advanced CKD.</p>
            </sec>
            <sec id="jah34260-sec-0024">
              <title>Sources of Funding</title>
              <p>The SPS3 (Secondary Prevention of Small Subcortical Strokes) Trial was conducted by SPS3 Trial investigators and supported by a grant (U01NS038529) from the National Institutes of Health–National Institute of Neurological Disorders and Stroke (NIH‐NINDS).</p>
            </sec>
            <sec id="jah34260-sec-0025">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah34260-sup-0001">
                <caption>
                  <p><bold>Table S1.</bold> Baseline Data for the 4 eGFR Subgroups</p>
                  <p><bold>Figure S1.</bold> Achieved blood pressures by randomized SBP intervention and 4 baseline eGFR subgroups.</p>
                  <p><bold>Figure S2.</bold> Forest plots with hazard ratios for the effect of SBP intervention on the events of primary and secondary outcomes by 4 eGFR subgroups.</p>
                </caption>
                <media xlink:href="JAH3-8-e013098-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah34260-sec-0023">
              <title>Acknowledgments</title>
              <p>We acknowledge and thank the study participants and investigators, without whom this trial would not have been possible. The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official interpretation of the US government.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah34260-bibl-0001">
              <title>References</title>
              <ref id="jah34260-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0001"><string-name><surname>Benavente</surname><given-names>OR</given-names></string-name>, <string-name><surname>White</surname><given-names>CL</given-names></string-name>, <string-name><surname>Pearce</surname><given-names>L</given-names></string-name>, <string-name><surname>Pergola</surname><given-names>P</given-names></string-name>, <string-name><surname>Roldan</surname><given-names>A</given-names></string-name>, <string-name><surname>Benavente</surname><given-names>MF</given-names></string-name>, <string-name><surname>Coffey</surname><given-names>C</given-names></string-name>, <string-name><surname>McClure</surname><given-names>LA</given-names></string-name>, <string-name><surname>Szychowski</surname><given-names>JM</given-names></string-name>, <string-name><surname>Conwit</surname><given-names>R</given-names></string-name>, <string-name><surname>Heberling</surname><given-names>PA</given-names></string-name>, <string-name><surname>Howard</surname><given-names>G</given-names></string-name>, <string-name><surname>Bazan</surname><given-names>C</given-names></string-name>, <string-name><surname>Vidal‐Pergola</surname><given-names>G</given-names></string-name>, <string-name><surname>Talbert</surname><given-names>R</given-names></string-name>, <string-name><surname>Hart</surname><given-names>RG</given-names></string-name>. <article-title>The secondary prevention of small subcortical strokes (SPS3) study</article-title>. <source xml:lang="en">Int J Stroke</source>. <year>2011</year>;<fpage>164</fpage>–<lpage>175</lpage>.<pub-id pub-id-type="pmid">21371282</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0002"><string-name><surname>Benavente</surname><given-names>OR</given-names></string-name>, <string-name><surname>Coffey</surname><given-names>CS</given-names></string-name>, <string-name><surname>Conwit</surname><given-names>R</given-names></string-name>, <string-name><surname>Hart</surname><given-names>RG</given-names></string-name>, <string-name><surname>McClure</surname><given-names>LA</given-names></string-name>, <string-name><surname>Pearce</surname><given-names>LA</given-names></string-name>, <string-name><surname>Pergola</surname><given-names>PE</given-names></string-name>, <string-name><surname>Szychowski</surname><given-names>JM</given-names></string-name>. <article-title>Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2013</year>;<fpage>507</fpage>–<lpage>515</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0003"><string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name><surname>MacLaughlin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Spencer</surname><given-names>CC</given-names></string-name>, <string-name><surname>Stafford</surname><given-names>RS</given-names></string-name>, <string-name><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Williams</surname><given-names>KA</given-names><suffix>Sr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2018</year>;<fpage>e127</fpage>–<lpage>e248</lpage>.<pub-id pub-id-type="pmid">29146535</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0004"><string-name><surname>Merai</surname><given-names>R</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>C</given-names></string-name>, <string-name><surname>Rakotz</surname><given-names>M</given-names></string-name>, <string-name><surname>Basch</surname><given-names>P</given-names></string-name>, <string-name><surname>Wright</surname><given-names>J</given-names></string-name>, <string-name><surname>Wong</surname><given-names>B</given-names></string-name>, <string-name><surname>Thorpe</surname><given-names>P</given-names></string-name>. <article-title>CDC grand rounds: a public health approach to detect and control hypertension</article-title>. <source xml:lang="en">MMWR Morb Mortal Wkly Rep</source>. <year>2016</year>;<fpage>1261</fpage>–<lpage>1264</lpage>.<pub-id pub-id-type="pmid">27855138</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="miscellaneous" id="jah34260-cit-0005"><collab collab-type="authors">CDC. Centers for Disease Control and Prevention</collab>
. <article-title>Chronic kidney disease surveillance system website</article-title>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0006"><string-name><surname>Horowitz</surname><given-names>B</given-names></string-name>, <string-name><surname>Miskulin</surname><given-names>D</given-names></string-name>, <string-name><surname>Zager</surname><given-names>P</given-names></string-name>. <article-title>Epidemiology of hypertension in CKD</article-title>. <source xml:lang="en">Adv Chronic Kidney Dis</source>. <year>2015</year>;<fpage>88</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">25704344</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0007"><string-name><surname>Ninomiya</surname><given-names>T</given-names></string-name>, <string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Turnbull</surname><given-names>F</given-names></string-name>, <string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name><surname>Barzi</surname><given-names>F</given-names></string-name>, <string-name><surname>Cass</surname><given-names>A</given-names></string-name>, <string-name><surname>Baigent</surname><given-names>C</given-names></string-name>, <string-name><surname>Chalmers</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>N</given-names></string-name>, <string-name><surname>Woodward</surname><given-names>M</given-names></string-name>, <string-name><surname>MacMahon</surname><given-names>S</given-names></string-name>. <article-title>Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta‐analysis of randomised controlled trials</article-title>. <source xml:lang="en">BMJ</source>. <year>2013</year>;<fpage>f5680</fpage>.<pub-id pub-id-type="pmid">24092942</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0008"><string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>JK</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Kimmel</surname><given-names>PL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Fine</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AK</given-names></string-name>, <string-name><surname>Ambrosius</surname><given-names>WT</given-names></string-name>. <article-title>A randomized trial of intensive versus standard blood‐pressure control</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2015</year>;<fpage>2103</fpage>–<lpage>2116</lpage>.<pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0009"><string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name><surname>MacLaughlin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Spencer</surname><given-names>CC</given-names></string-name>, <string-name><surname>Stafford</surname><given-names>RS</given-names></string-name>, <string-name><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Williams</surname><given-names>KA</given-names><suffix>Sr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source xml:lang="en">Hypertension</source>. <year>2018</year>;<fpage>e13</fpage>–<lpage>e115</lpage>.<pub-id pub-id-type="pmid">29133356</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0010"><string-name><surname>Kovesdy</surname><given-names>CP</given-names></string-name>. <article-title>The ideal blood pressure target for patients with chronic kidney disease‐searching for the sweet spot</article-title>. <source xml:lang="en">JAMA Intern Med</source>. <year>2017</year>;<fpage>1506</fpage>–<lpage>1507</lpage>.<pub-id pub-id-type="pmid">28873120</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0011"><string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Atkins</surname><given-names>E</given-names></string-name>, <string-name><surname>Lv</surname><given-names>J</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>A</given-names></string-name>, <string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name><surname>Ninomiya</surname><given-names>T</given-names></string-name>, <string-name><surname>Woodward</surname><given-names>M</given-names></string-name>, <string-name><surname>MacMahon</surname><given-names>S</given-names></string-name>, <string-name><surname>Turnbull</surname><given-names>F</given-names></string-name>, <string-name><surname>Hillis</surname><given-names>GS</given-names></string-name>, <string-name><surname>Chalmers</surname><given-names>J</given-names></string-name>, <string-name><surname>Mant</surname><given-names>J</given-names></string-name>, <string-name><surname>Salam</surname><given-names>A</given-names></string-name>, <string-name><surname>Rahimi</surname><given-names>K</given-names></string-name>, <string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Rodgers</surname><given-names>A</given-names></string-name>. <article-title>Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta‐analysis</article-title>. <source xml:lang="en">Lancet</source>. <year>2016</year>;<fpage>435</fpage>–<lpage>443</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0012"><string-name><surname>Obi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kalantar‐Zadeh</surname><given-names>K</given-names></string-name>, <string-name><surname>Shintani</surname><given-names>A</given-names></string-name>, <string-name><surname>Kovesdy</surname><given-names>CP</given-names></string-name>, <string-name><surname>Hamano</surname><given-names>T</given-names></string-name>. <article-title>Estimated glomerular filtration rate and the risk‐benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial</article-title>. <source xml:lang="en">J Intern Med</source>. <year>2018</year>;<fpage>314</fpage>–<lpage>327</lpage>.<pub-id pub-id-type="pmid">29044764</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0013"><string-name><surname>Hojs Fabjan</surname><given-names>T</given-names></string-name>, <string-name><surname>Hojs</surname><given-names>R</given-names></string-name>. <article-title>Stroke and renal dysfunction</article-title>. <source xml:lang="en">Eur J Intern Med</source>. <year>2014</year>;<fpage>18</fpage>–<lpage>24</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0014"><string-name><surname>El Husseini</surname><given-names>N</given-names></string-name>, <string-name><surname>Kaskar</surname><given-names>O</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>LB</given-names></string-name>. <article-title>Chronic kidney disease and stroke</article-title>. <source xml:lang="en">Adv Chronic Kidney Dis</source>. <year>2014</year>;<fpage>500</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">25443575</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0015"><string-name><surname>Masson</surname><given-names>P</given-names></string-name>, <string-name><surname>Webster</surname><given-names>AC</given-names></string-name>, <string-name><surname>Hong</surname><given-names>M</given-names></string-name>, <string-name><surname>Turner</surname><given-names>R</given-names></string-name>, <string-name><surname>Lindley</surname><given-names>RI</given-names></string-name>, <string-name><surname>Craig</surname><given-names>JC</given-names></string-name>. <article-title>Chronic kidney disease and the risk of stroke: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Nephrol Dial Transplant</source>. <year>2015</year>;<fpage>1162</fpage>–<lpage>1169</lpage>.<pub-id pub-id-type="pmid">25681099</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0016"><string-name><surname>Lee</surname><given-names>M</given-names></string-name>, <string-name><surname>Saver</surname><given-names>JL</given-names></string-name>, <string-name><surname>Chang</surname><given-names>KH</given-names></string-name>, <string-name><surname>Liao</surname><given-names>HW</given-names></string-name>, <string-name><surname>Chang</surname><given-names>SC</given-names></string-name>, <string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>. <article-title>Low glomerular filtration rate and risk of stroke: meta‐analysis</article-title>. <source xml:lang="en">BMJ</source>. <year>2010</year>;<fpage>c4249</fpage>.<pub-id pub-id-type="pmid">20884696</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0017"><string-name><surname>Chobanian</surname><given-names>AV</given-names></string-name>, <string-name><surname>Bakris</surname><given-names>GL</given-names></string-name>, <string-name><surname>Black</surname><given-names>HR</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Green</surname><given-names>LA</given-names></string-name>, <string-name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name><surname>Materson</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Roccella</surname><given-names>EJ</given-names></string-name>. <article-title>The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report</article-title>. <source xml:lang="en">JAMA</source>. <year>2003</year>;<fpage>2560</fpage>–<lpage>2572</lpage>.<pub-id pub-id-type="pmid">12748199</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0018"><string-name><surname>Levey</surname><given-names>AS</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>LA</given-names></string-name>, <string-name><surname>Schmid</surname><given-names>CH</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>YL</given-names></string-name>, <string-name><surname>Castro</surname><given-names>AF</given-names><suffix>III</suffix></string-name>, <string-name><surname>Feldman</surname><given-names>HI</given-names></string-name>, <string-name><surname>Kusek</surname><given-names>JW</given-names></string-name>, <string-name><surname>Eggers</surname><given-names>P</given-names></string-name>, <string-name><surname>Van Lente</surname><given-names>F</given-names></string-name>, <string-name><surname>Greene</surname><given-names>T</given-names></string-name>, <string-name><surname>Coresh</surname><given-names>J</given-names></string-name>. <article-title>A new equation to estimate glomerular filtration rate</article-title>. <source xml:lang="en">Ann Intern Med</source>. <year>2009</year>;<fpage>604</fpage>–<lpage>612</lpage>.<pub-id pub-id-type="pmid">19414839</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0019"><string-name><surname>Go</surname><given-names>AS</given-names></string-name>, <string-name><surname>Chertow</surname><given-names>GM</given-names></string-name>, <string-name><surname>Fan</surname><given-names>D</given-names></string-name>, <string-name><surname>McCulloch</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>CY</given-names></string-name>. <article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2004</year>;<fpage>1296</fpage>–<lpage>1305</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0020"><string-name><surname>Nickolas</surname><given-names>TL</given-names></string-name>, <string-name><surname>Khatri</surname><given-names>M</given-names></string-name>, <string-name><surname>Boden‐Albala</surname><given-names>B</given-names></string-name>, <string-name><surname>Kiryluk</surname><given-names>K</given-names></string-name>, <string-name><surname>Luo</surname><given-names>X</given-names></string-name>, <string-name><surname>Gervasi‐Franklin</surname><given-names>P</given-names></string-name>, <string-name><surname>Paik</surname><given-names>M</given-names></string-name>, <string-name><surname>Sacco</surname><given-names>RL</given-names></string-name>. <article-title>The association between kidney disease and cardiovascular risk in a multiethnic cohort: findings from the Northern Manhattan Study (NOMAS)</article-title>. <source xml:lang="en">Stroke</source>. <year>2008</year>;<fpage>2876</fpage>–<lpage>2879</lpage>.<pub-id pub-id-type="pmid">18617655</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0021"><string-name><surname>Nakayama</surname><given-names>M</given-names></string-name>, <string-name><surname>Metoki</surname><given-names>H</given-names></string-name>, <string-name><surname>Terawaki</surname><given-names>H</given-names></string-name>, <string-name><surname>Ohkubo</surname><given-names>T</given-names></string-name>, <string-name><surname>Kikuya</surname><given-names>M</given-names></string-name>, <string-name><surname>Sato</surname><given-names>T</given-names></string-name>, <string-name><surname>Nakayama</surname><given-names>K</given-names></string-name>, <string-name><surname>Asayama</surname><given-names>K</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>R</given-names></string-name>, <string-name><surname>Hashimoto</surname><given-names>J</given-names></string-name>, <string-name><surname>Totsune</surname><given-names>K</given-names></string-name>, <string-name><surname>Hoshi</surname><given-names>H</given-names></string-name>, <string-name><surname>Ito</surname><given-names>S</given-names></string-name>, <string-name><surname>Imai</surname><given-names>Y</given-names></string-name>. <article-title>Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study</article-title>. <source xml:lang="en">Nephrol Dial Transplant</source>. <year>2007</year>;<fpage>1910</fpage>–<lpage>1915</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0022"><article-title>Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack</article-title>. <source xml:lang="en">Lancet</source>. <year>2001</year>;<fpage>1033</fpage>–<lpage>1041</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0023"><string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, <string-name><surname>Diener</surname><given-names>HC</given-names></string-name>, <string-name><surname>Sacco</surname><given-names>RL</given-names></string-name>, <string-name><surname>Cotton</surname><given-names>D</given-names></string-name>, <string-name><surname>Ounpuu</surname><given-names>S</given-names></string-name>, <string-name><surname>Lawton</surname><given-names>WA</given-names></string-name>, <string-name><surname>Palesch</surname><given-names>Y</given-names></string-name>, <string-name><surname>Martin</surname><given-names>RH</given-names></string-name>, <string-name><surname>Albers</surname><given-names>GW</given-names></string-name>, <string-name><surname>Bath</surname><given-names>P</given-names></string-name>, <string-name><surname>Bornstein</surname><given-names>N</given-names></string-name>, <string-name><surname>Chan</surname><given-names>BP</given-names></string-name>, <string-name><surname>Chen</surname><given-names>ST</given-names></string-name>, <string-name><surname>Cunha</surname><given-names>L</given-names></string-name>, <string-name><surname>Dahlof</surname><given-names>B</given-names></string-name>, <string-name><surname>De Keyser</surname><given-names>J</given-names></string-name>, <string-name><surname>Donnan</surname><given-names>GA</given-names></string-name>, <string-name><surname>Estol</surname><given-names>C</given-names></string-name>, <string-name><surname>Gorelick</surname><given-names>P</given-names></string-name>, <string-name><surname>Gu</surname><given-names>V</given-names></string-name>, <string-name><surname>Hermansson</surname><given-names>K</given-names></string-name>, <string-name><surname>Hilbrich</surname><given-names>L</given-names></string-name>, <string-name><surname>Kaste</surname><given-names>M</given-names></string-name>, <string-name><surname>Lu</surname><given-names>C</given-names></string-name>, <string-name><surname>Machnig</surname><given-names>T</given-names></string-name>, <string-name><surname>Pais</surname><given-names>P</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>R</given-names></string-name>, <string-name><surname>Skvortsova</surname><given-names>V</given-names></string-name>, <string-name><surname>Teal</surname><given-names>P</given-names></string-name>, <string-name><surname>Toni</surname><given-names>D</given-names></string-name>, <string-name><surname>VanderMaelen</surname><given-names>C</given-names></string-name>, <string-name><surname>Voigt</surname><given-names>T</given-names></string-name>, <string-name><surname>Weber</surname><given-names>M</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>BW</given-names></string-name>. <article-title>Telmisartan to prevent recurrent stroke and cardiovascular events</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2008</year>;<fpage>1225</fpage>–<lpage>1237</lpage>.<pub-id pub-id-type="pmid">18753639</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0024"><string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Bath</surname><given-names>PM</given-names></string-name>, <string-name><surname>Cotton</surname><given-names>D</given-names></string-name>, <string-name><surname>Sha</surname><given-names>N</given-names></string-name>, <string-name><surname>Diener</surname><given-names>HC</given-names></string-name>. <article-title>Low glomerular filtration rate, recurrent stroke risk, and effect of renin‐angiotensin system modulation</article-title>. <source xml:lang="en">Stroke</source>. <year>2013</year>;<fpage>3223</fpage>–<lpage>3225</lpage>.<pub-id pub-id-type="pmid">23988639</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0025"><string-name><surname>Perkovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Ninomiya</surname><given-names>T</given-names></string-name>, <string-name><surname>Arima</surname><given-names>H</given-names></string-name>, <string-name><surname>Gallagher</surname><given-names>M</given-names></string-name>, <string-name><surname>Jardine</surname><given-names>M</given-names></string-name>, <string-name><surname>Cass</surname><given-names>A</given-names></string-name>, <string-name><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name><surname>Macmahon</surname><given-names>S</given-names></string-name>, <string-name><surname>Chalmers</surname><given-names>J</given-names></string-name>. <article-title>Chronic kidney disease, cardiovascular events, and the effects of perindopril‐based blood pressure lowering: data from the PROGRESS study</article-title>. <source xml:lang="en">J Am Soc Nephrol</source>. <year>2007</year>;<fpage>2766</fpage>–<lpage>2772</lpage>.<pub-id pub-id-type="pmid">17804673</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0026"><string-name><surname>Kovesdy</surname><given-names>CP</given-names></string-name>, <string-name><surname>Lu</surname><given-names>JL</given-names></string-name>, <string-name><surname>Molnar</surname><given-names>MZ</given-names></string-name>, <string-name><surname>Ma</surname><given-names>JZ</given-names></string-name>, <string-name><surname>Canada</surname><given-names>RB</given-names></string-name>, <string-name><surname>Streja</surname><given-names>E</given-names></string-name>, <string-name><surname>Kalantar‐Zadeh</surname><given-names>K</given-names></string-name>, <string-name><surname>Bleyer</surname><given-names>AJ</given-names></string-name>. <article-title>Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease</article-title>. <source xml:lang="en">JAMA Intern Med</source>. <year>2014</year>;<fpage>1442</fpage>–<lpage>1449</lpage>.<pub-id pub-id-type="pmid">25089540</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0027"><article-title>The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. The ARIC Investigators</article-title>. <source xml:lang="en">Am J Epidemiol</source>. <year>1989</year>;<fpage>687</fpage>–<lpage>702</lpage>.<pub-id pub-id-type="pmid">2646917</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0028"><string-name><surname>Fried</surname><given-names>LP</given-names></string-name>, <string-name><surname>Borhani</surname><given-names>NO</given-names></string-name>, <string-name><surname>Enright</surname><given-names>P</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>CD</given-names></string-name>, <string-name><surname>Gardin</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kronmal</surname><given-names>RA</given-names></string-name>, <string-name><surname>Kuller</surname><given-names>LH</given-names></string-name>, <string-name><surname>Manolio</surname><given-names>TA</given-names></string-name>, <string-name><surname>Mittelmark</surname><given-names>MB</given-names></string-name>, <string-name><surname>Newman</surname><given-names>A</given-names></string-name>. <article-title>The Cardiovascular Health Study: design and rationale</article-title>. <source xml:lang="en">Ann Epidemiol</source>. <year>1991</year>;<fpage>263</fpage>–<lpage>276</lpage>.<pub-id pub-id-type="pmid">1669507</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0029"><string-name><surname>Weiner</surname><given-names>DE</given-names></string-name>, <string-name><surname>Tighiouart</surname><given-names>H</given-names></string-name>, <string-name><surname>Levey</surname><given-names>AS</given-names></string-name>, <string-name><surname>Elsayed</surname><given-names>E</given-names></string-name>, <string-name><surname>Griffith</surname><given-names>JL</given-names></string-name>, <string-name><surname>Salem</surname><given-names>DN</given-names></string-name>, <string-name><surname>Sarnak</surname><given-names>MJ</given-names></string-name>. <article-title>Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease</article-title>. <source xml:lang="en">J Am Soc Nephrol</source>. <year>2007</year>;<fpage>960</fpage>–<lpage>966</lpage>.<pub-id pub-id-type="pmid">17301190</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0030"><string-name><surname>Cheung</surname><given-names>AK</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Craven</surname><given-names>TE</given-names></string-name>, <string-name><surname>Greene</surname><given-names>T</given-names></string-name>, <string-name><surname>Kimmel</surname><given-names>PL</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Hawfield</surname><given-names>AT</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Basile</surname><given-names>J</given-names></string-name>, <string-name><surname>Beddhu</surname><given-names>S</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>U</given-names></string-name>, <string-name><surname>Chang</surname><given-names>TI</given-names></string-name>, <string-name><surname>Chertow</surname><given-names>GM</given-names></string-name>, <string-name><surname>Chonchol</surname><given-names>M</given-names></string-name>, <string-name><surname>Freedman</surname><given-names>BI</given-names></string-name>, <string-name><surname>Haley</surname><given-names>W</given-names></string-name>, <string-name><surname>Ix</surname><given-names>JH</given-names></string-name>, <string-name><surname>Katz</surname><given-names>LA</given-names></string-name>, <string-name><surname>Killeen</surname><given-names>AA</given-names></string-name>, <string-name><surname>Papademetriou</surname><given-names>V</given-names></string-name>, <string-name><surname>Ricardo</surname><given-names>AC</given-names></string-name>, <string-name><surname>Servilla</surname><given-names>K</given-names></string-name>, <string-name><surname>Wall</surname><given-names>B</given-names></string-name>, <string-name><surname>Wolfgram</surname><given-names>D</given-names></string-name>, <string-name><surname>Yee</surname><given-names>J</given-names></string-name>. <article-title>Effects of intensive BP control in CKD</article-title>. <source xml:lang="en">J Am Soc Nephrol</source>. <year>2017</year>;<fpage>2812</fpage>–<lpage>2823</lpage>.<pub-id pub-id-type="pmid">28642330</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0031"><collab collab-type="authors">ACCORD Study Group</collab>
, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons‐Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail‐Beigi F. <article-title>Effects of intensive blood‐pressure control in type 2 diabetes mellitus</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2010</year>;<fpage>1575</fpage>–<lpage>1585</lpage>.<pub-id pub-id-type="pmid">20228401</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0032"><string-name><surname>Roger</surname><given-names>VL</given-names></string-name>, <string-name><surname>Go</surname><given-names>AS</given-names></string-name>, <string-name><surname>Lloyd‐Jones</surname><given-names>DM</given-names></string-name>, <string-name><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Berry</surname><given-names>JD</given-names></string-name>, <string-name><surname>Borden</surname><given-names>WB</given-names></string-name>, <string-name><surname>Bravata</surname><given-names>DM</given-names></string-name>, <string-name><surname>Dai</surname><given-names>S</given-names></string-name>, <string-name><surname>Ford</surname><given-names>ES</given-names></string-name>, <string-name><surname>Fox</surname><given-names>CS</given-names></string-name>, <string-name><surname>Fullerton</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Gillespie</surname><given-names>C</given-names></string-name>, <string-name><surname>Hailpern</surname><given-names>SM</given-names></string-name>, <string-name><surname>Heit</surname><given-names>JA</given-names></string-name>, <string-name><surname>Howard</surname><given-names>VJ</given-names></string-name>, <string-name><surname>Kissela</surname><given-names>BM</given-names></string-name>, <string-name><surname>Kittner</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lackland</surname><given-names>DT</given-names></string-name>, <string-name><surname>Lichtman</surname><given-names>JH</given-names></string-name>, <string-name><surname>Lisabeth</surname><given-names>LD</given-names></string-name>, <string-name><surname>Makuc</surname><given-names>DM</given-names></string-name>, <string-name><surname>Marcus</surname><given-names>GM</given-names></string-name>, <string-name><surname>Marelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Matchar</surname><given-names>DB</given-names></string-name>, <string-name><surname>Moy</surname><given-names>CS</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Mussolino</surname><given-names>ME</given-names></string-name>, <string-name><surname>Nichol</surname><given-names>G</given-names></string-name>, <string-name><surname>Paynter</surname><given-names>NP</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>EZ</given-names></string-name>, <string-name><surname>Sorlie</surname><given-names>PD</given-names></string-name>, <string-name><surname>Sotoodehnia</surname><given-names>N</given-names></string-name>, <string-name><surname>Turan</surname><given-names>TN</given-names></string-name>, <string-name><surname>Virani</surname><given-names>SS</given-names></string-name>, <string-name><surname>Wong</surname><given-names>ND</given-names></string-name>, <string-name><surname>Woo</surname><given-names>D</given-names></string-name>, <string-name><surname>Turner</surname><given-names>MB</given-names></string-name>. <article-title>Heart disease and stroke statistics—2012 update: a report from the American Heart Association</article-title>. <source xml:lang="en">Circulation</source>. <year>2012</year>;<fpage>e2</fpage>–<lpage>e220</lpage>.<pub-id pub-id-type="pmid">22179539</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0033"><string-name><surname>MacMahon</surname><given-names>S</given-names></string-name>, <string-name><surname>Peto</surname><given-names>R</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>J</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, <string-name><surname>Sorlie</surname><given-names>P</given-names></string-name>, <string-name><surname>Neaton</surname><given-names>J</given-names></string-name>, <string-name><surname>Abbott</surname><given-names>R</given-names></string-name>, <string-name><surname>Godwin</surname><given-names>J</given-names></string-name>, <string-name><surname>Dyer</surname><given-names>A</given-names></string-name>, <string-name><surname>Stamler</surname><given-names>J</given-names></string-name>. <article-title>Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias</article-title>. <source xml:lang="en">Lancet</source>. <year>1990</year>;<fpage>765</fpage>–<lpage>774</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34260-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0034"><string-name><surname>Go</surname><given-names>AS</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Roger</surname><given-names>VL</given-names></string-name>, <string-name><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Berry</surname><given-names>JD</given-names></string-name>, <string-name><surname>Borden</surname><given-names>WB</given-names></string-name>, <string-name><surname>Bravata</surname><given-names>DM</given-names></string-name>, <string-name><surname>Dai</surname><given-names>S</given-names></string-name>, <string-name><surname>Ford</surname><given-names>ES</given-names></string-name>, <string-name><surname>Fox</surname><given-names>CS</given-names></string-name>, <string-name><surname>Franco</surname><given-names>S</given-names></string-name>, <string-name><surname>Fullerton</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Gillespie</surname><given-names>C</given-names></string-name>, <string-name><surname>Hailpern</surname><given-names>SM</given-names></string-name>, <string-name><surname>Heit</surname><given-names>JA</given-names></string-name>, <string-name><surname>Howard</surname><given-names>VJ</given-names></string-name>, <string-name><surname>Huffman</surname><given-names>MD</given-names></string-name>, <string-name><surname>Kissela</surname><given-names>BM</given-names></string-name>, <string-name><surname>Kittner</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lackland</surname><given-names>DT</given-names></string-name>, <string-name><surname>Lichtman</surname><given-names>JH</given-names></string-name>, <string-name><surname>Lisabeth</surname><given-names>LD</given-names></string-name>, <string-name><surname>Magid</surname><given-names>D</given-names></string-name>, <string-name><surname>Marcus</surname><given-names>GM</given-names></string-name>, <string-name><surname>Marelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Matchar</surname><given-names>DB</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>DK</given-names></string-name>, <string-name><surname>Mohler</surname><given-names>ER</given-names></string-name>, <string-name><surname>Moy</surname><given-names>CS</given-names></string-name>, <string-name><surname>Mussolino</surname><given-names>ME</given-names></string-name>, <string-name><surname>Nichol</surname><given-names>G</given-names></string-name>, <string-name><surname>Paynter</surname><given-names>NP</given-names></string-name>, <string-name><surname>Schreiner</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Sorlie</surname><given-names>PD</given-names></string-name>, <string-name><surname>Stein</surname><given-names>J</given-names></string-name>, <string-name><surname>Turan</surname><given-names>TN</given-names></string-name>, <string-name><surname>Virani</surname><given-names>SS</given-names></string-name>, <string-name><surname>Wong</surname><given-names>ND</given-names></string-name>, <string-name><surname>Woo</surname><given-names>D</given-names></string-name>, <string-name><surname>Turner</surname><given-names>MB</given-names></string-name>. <article-title>Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association</article-title>. <source xml:lang="en">Circulation</source>. <year>2013</year>;<fpage>143</fpage>–<lpage>152</lpage>.<pub-id pub-id-type="pmid">23283859</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0035"><string-name><surname>Gueyffier</surname><given-names>F</given-names></string-name>, <string-name><surname>Boissel</surname><given-names>JP</given-names></string-name>, <string-name><surname>Boutitie</surname><given-names>F</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>S</given-names></string-name>, <string-name><surname>Coope</surname><given-names>J</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>J</given-names></string-name>, <string-name><surname>Ekbom</surname><given-names>T</given-names></string-name>, <string-name><surname>Fagard</surname><given-names>R</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>L</given-names></string-name>, <string-name><surname>Kerlikowske</surname><given-names>K</given-names></string-name>, <string-name><surname>Perry</surname><given-names>M</given-names></string-name>, <string-name><surname>Prineas</surname><given-names>R</given-names></string-name>, <string-name><surname>Schron</surname><given-names>E</given-names></string-name>. <article-title>Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (individual data analysis of antihypertensive intervention trials) Project Collaborators</article-title>. <source xml:lang="en">Stroke</source>. <year>1997</year>;<fpage>2557</fpage>–<lpage>2562</lpage>.<pub-id pub-id-type="pmid">9412649</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0036"><string-name><surname>Rashid</surname><given-names>P</given-names></string-name>, <string-name><surname>Leonardi‐Bee</surname><given-names>J</given-names></string-name>, <string-name><surname>Bath</surname><given-names>P</given-names></string-name>. <article-title>Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review</article-title>. <source xml:lang="en">Stroke</source>. <year>2003</year>;<fpage>2741</fpage>–<lpage>2748</lpage>.<pub-id pub-id-type="pmid">14576382</pub-id></mixed-citation>
              </ref>
              <ref id="jah34260-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah34260-cit-0037"><string-name><surname>Arboix</surname><given-names>A</given-names></string-name>, <string-name><surname>Marti‐Vilalta</surname><given-names>JL</given-names></string-name>. <article-title>Lacunar stroke</article-title>. <source xml:lang="en">Expert Rev Neurother</source>. <year>2009</year>;<fpage>179</fpage>–<lpage>196</lpage>.<pub-id pub-id-type="pmid">19210194</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
